Can talking therapy boost recovery after stem cell transplants?

NCT ID NCT07516314

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a type of talk therapy called Acceptance and Commitment Therapy (ACT) for people getting stem cell transplants. The goal is to help patients and their caregivers stick with physical activity and healthy eating during a tough recovery. Researchers will measure if it improves physical function, hospital stay length, and survival in 476 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acceptance and Commitment Therapy (ACT) sessions
What this could lead to
If it works, this could help stem cell transplant patients maintain physical function and reduce complications during recovery.
What could go wrong
This is a phase 2 trial, so results are still uncertain. The therapy may not improve physical function or survival, and it requires patient and caregiver commitment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 476 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria: * Ability of participant to understand this study, and participant willingness to sign a written informed consent. NOTE: Remote / electronic consent via REDCap consenting allowed per IRB policy and approval. * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Plan to undergo allogeneic HCT in approximately 30 days * Males and/or females age 18 - 80 years * Agreement to adhere to Lifestyle Considerations throughout study duration * Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access). NOTE: A smartphone will be provided to participants if needed. * Able to read/write English or Spanish (as we lack trained ACT interventionists in other languages) Caregiver Inclusion Criteria: * Ability of participant to understand this study, and participant willingness to sign a written informed consent. NOTE: Remote / electronic consent via REDCap consenting allowed per IRB policy and approval. * Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study * Males and/or females age 18-80 years * Agreement to adhere to Lifestyle Considerations throughout study duration * Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access). NOTE: A smartphone will be provided to participants if needed. * Able to read/write English or Spanish (as we lack trained ACT interventionists in other languages) Patient Exclusion Criteria: * Caregiver unwilling to enroll (as standard of care, all HCT patients are required to have a caregiver, but caregivers may decline to participate in this study which would make the patient ineligible for this study) * Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements * Concurrent participation in another behavioral intervention research study. * Activity restrictions that limit one's ability to engage in intense physical activity Caregiver Exclusion Criteria: * Patient unwilling to enroll * Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements • Concurrent participation in another behavioral intervention research study. * Activity restrictions that limit one's ability to engage in intense physical activity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stem cell transplant patients are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University

    Durham, North Carolina, 27705, United States

  • University of Kansas Cancer Center

    Kansas City, Kansas, 66160, United States